The emerging immunogenomic landscape of uveal melanoma and therapeutic implications

21 mars - 17h15 - 23h59

Centre de recherche - Paris

Amphithéâtre Constant-Burg - 12 rue Lhomond, Paris 5e

12 rue Lhomond, Paris 5ème

Description

Uveal melanoma responds poorly to checkpoint inhibitor immunotherapy, which has been attributed to low mutation burden. Additionally, there is growing evidence that uveal melanomas actively suppress the tumor immune microenvironment via recurrent genetic aberrations such as BAP1 mutations. The role of recurrent genetic aberrations in immune evasion and potential therapeutic strategies will be discussed.

 

The seminar will also be broadcasted online via Teams

Orateurs

J. William Harbour

UT Southwestern Medical Center

Invité(es) par

The Uveal Melanoma Medico-Scientific Program

Une question sur le séminaire ?

The Uveal Melanoma Medico-Scientific Program

leanne.de-koning@curie.fr